MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
3.435
+0.055
+1.63%
After Hours: 3.500 +0.065 +1.89% 18:52 01/07 EST
OPEN
3.500
PREV CLOSE
3.380
HIGH
3.590
LOW
3.400
VOLUME
86.45K
TURNOVER
--
52 WEEK HIGH
27.00
52 WEEK LOW
2.738
MARKET CAP
7.78M
P/E (TTM)
-0.0981
1D
5D
1M
3M
1Y
5Y
1D
Processa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance
TipRanks · 21h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 23h ago
Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Processa Pharmaceuticals completes enrollment of 20th patient in Phase 2 study
TipRanks · 2d ago
Processa Completes Enrollment And Dosing Of 20 Patients For Planned Formal Interim Analysis In Ongoing Phase 2 Clinical Study Evaluating NGC-Cap In Patients With Breast Cancer; Interim Data To Be Reported In Q1
Benzinga · 2d ago
Processa Pharmaceuticals Completes Enrollment for Interim Analysis in Phase 2 Breast Cancer Study
Reuters · 2d ago
Weekly Report: what happened at PCSA last week (1229-0102)?
Weekly Report · 3d ago
Weekly Report: what happened at PCSA last week (1222-1226)?
Weekly Report · 12/29/2025 09:48
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.